Patient Management
Cloud-based platform for healthcare professionals to manage chronic disease patients efficiently
Platform · Cloud SaaSCompany source
Company profile
About Health2Sync
Health2Sync is a digital health company that delivers personalized chronic disease management solutions, with a primary focus on diabetes care. Founded in 2013 in Taiwan, the company has grown to serve over 1 million registered users worldwide across Asia, the Middle East, and other regions. The Health2Sync platform consists of two core products: a patient-facing mobile app that allows users to log and visualize blood glucose, blood pressure, weight readings, and daily activities, and a Patient Management Platform that enables healthcare professionals to monitor and support patients remotely. The company's mission is to alleviate the problem of insufficient medical resources by empowering patients to take control of their health through smart tools and data analytics. Health2Sync integrates with various medical devices including continuous glucose monitors (CGMs), digital insulin pens, and fitness trackers to provide comprehensive health data syncing. The platform offers AI-powered features such as food recognition for meal logging and voice recording for health data entry. Clinical outcomes data shows that users with an initial HbA1c greater than 7% experience an average 2.0% drop in HbA1c after 3 months of using Health2Sync. The company has established strategic partnerships with major pharmaceutical companies including Sanofi, Novo Nordisk, and AstraZeneca, and has deployed its Patient Management Platform to over 240 clinics globally. Health2Sync is certified under ISO 27001:2022 and ISO 27017:2015 for information security management.
Company description Health2Sync official website
Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Health2Sync?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Chronic kidney disease (CKD)
- Diabetes
- General chronic disease management
- Hypertension
- Obesity
Who it serves
- Clinics
- Corporate health insurance (Kenpo)
- Health systems
- Individual patients
- Payers
- Pharma companies
Deployment & integration
Cloud Saas · Embedded deployment with recorded integration context.
Recorded integration context: Abbott FreeStyle LibreLink, Biocorp Mallya Cap, Fitbit, Google Health Connect, Novo Nordisk NovoPen 6, Novo Nordisk NovoPen Echo Plus, Sanofi SoloSmart, Taiwan National Health Insurance My Health Bank.
Geographic context
MarketsAustralia · Egypt · France · Hong Kong · Japan · Malaysia · Middle East · Singapore · South Korea · Taiwan · USA
Company sourceOfficial website
Company milestones
Platform expansion
Completed oversubscribed US$20M funding round (March 2025). Listed on Taiwan Emerging Stock Market under ticker 7851 (November 2024). Named to Forbes 'Asia 100 To Watch 2025' (August 2024). Launched DigiCoach CGM-based diabetes prevention program with Singapore Health Promotion Board (August 2024). Selected for Taiwan's Digital Care Reimbursement Project (October 2024). Reached 1 million registered users (January 2023).
Partnerships
Recorded partners
- Abbott
- AstraZeneca
- Biocorp
- Fitbit
- Hitachi
- Novo Nordisk
- NTT
- Sanofi
- Singapore Health Promotion Board
- Taiwan National Health Insurance Administration
- Western Sydney Diabetes
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Data Syncing
Device integration service for seamless health data synchronization
Api · EmbeddedCompany source
DigiCoach
CGM-based diabetes prevention program developed with Singapore's Health Promotion Board
Service · Cloud SaaSCompany source
Health2Sync App
Mobile app for chronic disease management with blood glucose, blood pressure, and weight tracking
Software · Cloud SaaSCompany source
Insultrate
First basal insulin titration Software-as-Medical Device approved in Taiwan
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)NCT06271200 · Mentioned · RECRUITING
A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in TaiwanNCT05684341 · Mentioned · COMPLETED
Effectiveness of Health Management of Glycemic Control and Physical Activity in Type 2 Diabetes Mellitus Using Smartphone ApplicationNCT04631159 · Mentioned · UNKNOWN
Glucometer and Mobile-phone Based Data Transfer System in DiabetesNCT02769377 · Mentioned · UNKNOWN
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
2.0% average HbA1c reduction
After 3 months of use for users with initial HbA1c > 7%
Hitachi Corporate Health Insurance (Kenpo)
Nationwide corporate health insurance partnership for employee diabetes management
NTT Corporate Health Insurance (Kenpo)
Nationwide corporate health insurance partnership for employee diabetes management
Taiwan National Health Insurance Administration
Digital Care Reimbursement Project participation
Singapore Health Promotion Board
Co-development of DigiCoach CGM-based diabetes prevention program
Western Sydney Diabetes
Streamline patient care workflow using Health2Sync solution
Health2Sync User Base (HbA1c > 7%)
Diabetes management and blood glucose control for patients with elevated HbA1c levels
2.0% drop in HbA1c after 3 months of using Health2Sync for users with initial HbA1c > 7%
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Ed Deng
CEO
06 · Company updates
Updates from Health2Sync
Recent articles published on Health2Sync's official website.
Alcohol & Diabetes: Risks, Limits & Safer Picks
Read on Health2SyncCan I Have Honey If I Have Diabetes?
Read on Health2SyncCan People with Diabetes Eat Oatmeal? How to Choose and Eat It Right
Read on Health2SyncWhat to Drink When You Have Diabetes: Tips, Best and Worst Drinks
Read on Health2SyncBest Breads for People with Diabetes: A Simple Guide
Read on Health2Sync07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Chronic Disease Management & Digital Therapeutics
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.